These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Teng F; Meng X; Kong L; Yu J Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348 [TBL] [Abstract][Full Text] [Related]
5. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D Science; 2018 Oct; 362(6411):. PubMed ID: 30309915 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Immunotherapy: Current Developments and Challenges. Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758 [TBL] [Abstract][Full Text] [Related]
13. The influence of microenvironment on tumor immunotherapy. Zhang J; Shi Z; Xu X; Yu Z; Mi J FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790 [TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259 [TBL] [Abstract][Full Text] [Related]
15. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Parchment RE; Voth AR; Doroshow JH; Berzofsky JA Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482 [TBL] [Abstract][Full Text] [Related]
16. T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. Sioud M Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29381830 [TBL] [Abstract][Full Text] [Related]
17. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. Jia Q; Wang J; He N; He J; Zhu B JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729 [TBL] [Abstract][Full Text] [Related]
18. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419 [TBL] [Abstract][Full Text] [Related]
19. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939 [TBL] [Abstract][Full Text] [Related]
20. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related] [Next] [New Search]